Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Works matching IS 01676997 AND DT 2011 AND VI 29 AND IP 5
Results: 54
1
2
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
3
Phase I trial of oblimersen (Genasense(R)) and gemcitabine in refractory and advanced malignancies.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
4
Intercalative pyrimido[4',5':4,5]thieno(2,3-b)quinolines induce apoptosis in leukemic cells: a comparative study of methoxy and morpholino substitution.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
5
5k, a novel [beta]-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
6
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 953, doi. 10.1007/s10637-010-9405-7
- By:
- Publication type:
- Article
7
D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase II[alpha].
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
8
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 984, doi. 10.1007/s10637-010-9437-z
- By:
- Publication type:
- Article
9
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1021, doi. 10.1007/s10637-010-9392-8
- By:
- Publication type:
- Article
10
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1029, doi. 10.1007/s10637-010-9399-1
- By:
- Publication type:
- Article
11
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1045, doi. 10.1007/s10637-010-9408-4
- By:
- Publication type:
- Article
12
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1073, doi. 10.1007/s10637-010-9418-2
- By:
- Publication type:
- Article
13
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1038, doi. 10.1007/s10637-010-9400-z
- By:
- Publication type:
- Article
14
In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 742, doi. 10.1007/s10637-010-9412-8
- By:
- Publication type:
- Article
15
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 752, doi. 10.1007/s10637-010-9415-5
- By:
- Publication type:
- Article
16
Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 719, doi. 10.1007/s10637-010-9407-5
- By:
- Publication type:
- Article
17
An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 760, doi. 10.1007/s10637-010-9419-1
- By:
- Publication type:
- Article
18
Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1050, doi. 10.1007/s10637-010-9409-3
- By:
- Publication type:
- Article
19
A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 777, doi. 10.1007/s10637-010-9422-6
- By:
- Publication type:
- Article
20
MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 846, doi. 10.1007/s10637-010-9432-4
- By:
- Publication type:
- Article
21
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1066, doi. 10.1007/s10637-010-9417-3
- By:
- Publication type:
- Article
22
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1057, doi. 10.1007/s10637-010-9413-7
- By:
- Publication type:
- Article
23
The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 811, doi. 10.1007/s10637-010-9426-2
- By:
- Publication type:
- Article
24
5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 786, doi. 10.1007/s10637-010-9423-5
- By:
- Publication type:
- Article
25
D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 800, doi. 10.1007/s10637-010-9425-3
- By:
- Publication type:
- Article
26
The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 730, doi. 10.1007/s10637-010-9410-x
- By:
- Publication type:
- Article
27
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 971, doi. 10.1007/s10637-010-9416-4
- By:
- Publication type:
- Article
28
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 818, doi. 10.1007/s10637-010-9429-z
- By:
- Publication type:
- Article
29
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 978, doi. 10.1007/s10637-010-9427-1
- By:
- Publication type:
- Article
30
Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 768, doi. 10.1007/s10637-010-9421-7
- By:
- Publication type:
- Article
31
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 963, doi. 10.1007/s10637-010-9414-6
- By:
- Publication type:
- Article
32
A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 861, doi. 10.1007/s10637-010-9435-1
- By:
- Publication type:
- Article
33
Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 827, doi. 10.1007/s10637-010-9430-6
- By:
- Publication type:
- Article
34
Intercalative pyrimido[4′,5′:4,5]thieno(2,3-b)quinolines induce apoptosis in leukemic cells: a comparative study of methoxy and morpholino substitution.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 873, doi. 10.1007/s10637-010-9436-0
- By:
- Publication type:
- Article
35
Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 833, doi. 10.1007/s10637-010-9431-5
- By:
- Publication type:
- Article
36
NSC126188, a piperazine alkyl derivative, induces apoptosis via upregulation of RhoB in HeLa cells.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 853, doi. 10.1007/s10637-010-9433-3
- By:
- Publication type:
- Article
37
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer.
- Published in:
- 2011
- By:
- Publication type:
- Report
38
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 891, doi. 10.1007/s10637-010-9441-3
- By:
- Publication type:
- Article
39
A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 996, doi. 10.1007/s10637-010-9444-0
- By:
- Publication type:
- Article
40
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1004, doi. 10.1007/s10637-010-9447-x
- By:
- Publication type:
- Article
41
Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 945, doi. 10.1007/s10637-010-9450-2
- By:
- Publication type:
- Article
42
Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 883, doi. 10.1007/s10637-010-9439-x
- By:
- Publication type:
- Article
43
Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 932, doi. 10.1007/s10637-010-9449-8
- By:
- Publication type:
- Article
44
Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 912, doi. 10.1007/s10637-010-9446-y
- By:
- Publication type:
- Article
45
Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan.
- Published in:
- 2011
- By:
- Publication type:
- Report
46
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 901, doi. 10.1007/s10637-010-9445-z
- By:
- Publication type:
- Article
47
A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 1013, doi. 10.1007/s10637-010-9456-9
- By:
- Publication type:
- Article
48
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model.
- Published in:
- 2011
- By:
- Publication type:
- Report
49
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 5, p. 921, doi. 10.1007/s10637-010-9448-9
- By:
- Publication type:
- Article
50
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
- Published in:
- 2011
- By:
- Publication type:
- Report